# phase 1 adaptive dose-escalation study of mycophenolate mofetil (MMF) in combination with temozolomide (TMZ) for patients with newly diagnosed glioblastoma

> **NIH NIH P50** · NORTHWESTERN UNIVERSITY · 2020 · $342,106


## Key facts

- **NIH application ID:** 10468352
- **Project number:** 5P50CA221747-03
- **Recipient organization:** NORTHWESTERN UNIVERSITY
- **Principal Investigator:** MACIEJ S LESNIAK
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $342,106
- **Award type:** 5
- **Project period:** 2020-08-01 → 2023-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10468352

## Citation

> US National Institutes of Health, RePORTER application 10468352, phase 1 adaptive dose-escalation study of mycophenolate mofetil (MMF) in combination with temozolomide (TMZ) for patients with newly diagnosed glioblastoma (5P50CA221747-03). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10468352. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*